DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Alan H Bryce; Oliver Sartor; Johann de Bono

doi:10.1016/j.eururo.2020.06.020

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

Eur Urol. 2020 Oct;78(4):486-488. doi: 10.1016/j.eururo.2020.06.020. Epub 2020 Jul 5.

Authors

Alan H Bryce¹, Oliver Sartor², Johann de Bono³

Affiliations

¹ Department of Oncology, Mayo Clinic, Scottsdale, AZ, USA.
² Cancer Center, Tulane Medical School, New Orleans, LA, USA. Electronic address: [email protected].
³ Experimental Cancer Medicine, Institute for Cancer Research, London, UK; Royal Marsden Hospital, London, UK.

PMID: 32636098
DOI: 10.1016/j.eururo.2020.06.020

Abstract

Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.

Publication types

Editorial

MeSH terms

DNA Repair* / drug effects
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / genetics*

Substances

Poly(ADP-ribose) Polymerase Inhibitors